Investors lose patience with Trovagene

Shares of thinly traded nano cap Trovagene (TROV -8.8%) continue their slide today on 4x higher volume. Prices have now cratered 66% from the $10.27 August 5 high.

The company reported Q1 results earlier in the week. Notable by their absence are any revenues from its much-ballyhooed transrenal nucleic acid tests. It launched a BRAF test in its CLIA lab in October of last year and a KRAS test in March, but no revenues have been generated yet. Per its 10-Q, all of its $111K in revenues come from NPM1 royalties.

Comments (6)
  • 1880gh
    , contributor
    Comments (94) | Send Message
    whats going on help mike h
    16 May 2014, 05:30 PM Reply Like
  • motie10
    , contributor
    Comments (2) | Send Message
    Was any explanation for the lack of revenues offered during the conference call? The KRAS test is probably too new, but the BRAF test has been available for 6 months.
    16 May 2014, 05:50 PM Reply Like
  • jake319
    , contributor
    Comments (107) | Send Message
    Mmmmm Could this be another pump and dump?
    16 May 2014, 08:11 PM Reply Like
  • ceristeare
    , contributor
    Comments (1134) | Send Message
    Someone bought this stock at 10 bucks?? Way too early, I like it here and on the way down
    16 May 2014, 09:54 PM Reply Like
  • GetOffMyLawn
    , contributor
    Comments (19) | Send Message
    ...and their likewise ballyhooed HPV test, launched OVER a YEAR ago, generated precisely ZERO $. Not only was it scrubbed from website but those foreign collaborations were erased. 10Q sez Perkin Elmer also terminated agreement. Seems they cant beat a pair of twos.
    18 May 2014, 08:01 PM Reply Like
  • ceristeare
    , contributor
    Comments (1134) | Send Message
    They are building a portfolio of scalable products, collecting patents, value, etc. Marketing products? We'll see.
    18 May 2014, 11:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs